(Reuters) - Merck & Co has put on fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval, in an attempt to close the gap with competitors in two lucrative segments, the Wall Street Journal reported. The drugmaker will file an application midyear for U.S. regulatory approval to expand the use of its new cancer immunotherapy Keytruda to include the treatment of non-small-cell lung cancer, the most common form of the deadly disease, the Journal reported. (http://on.wsj. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment